Chinese Biotech Firm Aims to Beat Foreign Rivals on Price With New Cancer Drug
* Company is in talks with local authorities to make its PD-1 inhibitor eligible for reimbursement by government insurance plans — a key part of the goal to offer the drug at such a low price
* Medicine is used to treat certain types of melanoma, a disease that killed about 3,800 people in China in 2018
(Beijing) — Shanghai Junshi Biosciences Co. Ltd. aims to sell its recently approved cancer drug for far less than its overseas competitors, though the plan rests on local governments agreeing to pay part of the cost.
Toripalimab will be sold to major city hospitals and pharmacies for around a third of the price of the U.S.-based Merck & Co.’s rival medicine, Junshi Biosciences CEO Li Ning told Caixin on Thursday. Merck’s Keytruda goes for about 300,000 yuan ($43,600) per course of treatment.
The other similar foreign-made drug approved for sale in China is made by U.S. company Bristol-Myers Squibb Co. and costs around 135,000 yuan per course. A fourth drug, made by local firm Innovent Biologics Inc., was approved at the end of last year, but its price has not been revealed.
“Junshi Biosciences has recruited a business team of around 200 people to promote the drug,” Li said.
Toripalimab belongs to a group of drugs known as PD-1 inhibitors, which work by reversing the cancer’s suppression of a patient’s immune system and thus help the immune system target cancer cells.
Li said the company is in talks with local authorities to make its PD-1 inhibitor eligible for reimbursement by government insurance plans. This will be key if the company is to offer the drug — its first to go on sale — at such a low price.
The medicine is used to treat certain types of melanoma. According to figures from the Global Cancer Observatory, about 3,800 people in China died of melanoma in 2018, and 7,400 new cases were diagnosed.
Junshi Biosciences in December raised about $394 million in a Hong Kong initial public offering. The money-losing biotech startup reported in its prospectus that most of its revenue was earned by providing consulting services and not drug sales.
Shares of the company closed at HK$23.25 ($2.97) on Thursday, down 0.43% from the opening price.
Contact reporter Tang Ziyi (firstname.lastname@example.org)
Dec 14 04:16
Dec 14 04:48
Dec 13 16:21
Dec 13 14:30
Dec 13 14:18
Dec 13 14:43
Dec 13 11:37
Dec 13 10:13
Dec 13 06:16
Dec 13 04:49
Dec 12 18:46
- 1JD.com’s Richard Liu Steps Down From Key Positions, but Retains Control
- 2In Depth: How the Queen of Gree Won, Again
- 3Another Local Government Financing Vehicle Fails to Pay Bond Interest
- 4China’s Curing Cancer Faster and Cheaper Than Anywhere Else
- 5Exclusive: Tewoo Offshore Bondholders Take Heavy Losses to Exit
- 1Power To The People: Pintec Serves A Booming Consumer Class
- 2Largest hotel group in Europe accepts UnionPay
- 3UnionPay mobile QuickPass debuts in Hong Kong
- 4UnionPay International launches premium catering privilege U Dining Collection
- 5UnionPay International’s U Plan has covered over 1600 stores overseas